Expert Guidance on Navigating the Evolving Head and Neck Cancer Treatment Continuum: What Matters Now and How to Apply It in Practice

This activity examines the distinct biology prognosis and treatment needs of HPVassociated and HPVunrelated head and neck squamous cell carcinoma HNSCC across locoregionally advanced and recurrentmetastatic disease Expert faculty review evidence supporting evolving multimodality strategies including perioperative pembrolizumab from KEYNOTE689 postoperative nivolumab with chemoradiotherapy from NIVOPOSTOP and investigational neoadjuvant immunotherapy combinations while discussing the importance of PDL1 CPS treatment timing pathologic response and riskadapted postoperative therapy Faculty also evaluate established treatment sequencing based on KEYNOTE048 and emerging approaches for recurrentmetastatic HNSCC including EGFR MET TGF and LGR5directed therapies and antibodydrug conjugates with attention to efficacy safety biomarker limitations and supportive care These data help learners individualize therapy while balancing survival response urgency toxicity organ preservation and functional outcomes

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Target Specialties

Pricing

Free

Reported to ACCME by the provider

On-demand / recorded video
Credit · Up to 1.5 credits
MOC · Up to 1.5 points
Commercial Support

Released

Aug 10, 2026
Last day to claim credit

Feb 10, 2027 4 months left

Expert Guidance on Navigating the Evolving Head and Neck Cancer Treatment Continuum: What Matters Now and How to Apply It in Practice

Related courses

More from Clinical Care Options, LLC (dba Decera Clinical Education)